MX2022000052A - Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766. - Google Patents

Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766.

Info

Publication number
MX2022000052A
MX2022000052A MX2022000052A MX2022000052A MX2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A MX 2022000052 A MX2022000052 A MX 2022000052A
Authority
MX
Mexico
Prior art keywords
increase therapeutic
antineoplastic compound
therapeutic compliance
compliance
cancer
Prior art date
Application number
MX2022000052A
Other languages
English (en)
Spanish (es)
Inventor
Rongrong Jiang
Vaishali Dixit
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2022000052A publication Critical patent/MX2022000052A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022000052A 2019-07-01 2020-07-01 Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766. MX2022000052A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869389P 2019-07-01 2019-07-01
PCT/US2020/040515 WO2021003279A1 (en) 2019-07-01 2020-07-01 System for enhancing therapeutic compliance of the anti-cancer compound e7766

Publications (1)

Publication Number Publication Date
MX2022000052A true MX2022000052A (es) 2022-04-06

Family

ID=71895194

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000052A MX2022000052A (es) 2019-07-01 2020-07-01 Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766.

Country Status (10)

Country Link
US (1) US12564600B2 (cg-RX-API-DMAC7.html)
EP (1) EP3993809B1 (cg-RX-API-DMAC7.html)
JP (1) JP7704690B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220029717A (cg-RX-API-DMAC7.html)
CN (1) CN114599374A (cg-RX-API-DMAC7.html)
AU (1) AU2020300543A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026876A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145824A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022000052A (cg-RX-API-DMAC7.html)
WO (1) WO2021003279A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4398901A1 (en) 2021-09-09 2024-07-17 Eisai R&D Management Co., Ltd. Biomarkers for sting agonists and methods of using the same
CN115512788B (zh) * 2022-09-16 2023-08-08 山东大学 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446893A1 (en) 2010-11-01 2012-05-02 Bergen Teknologioverføring AS Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters
WO2013169616A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmacokinetic modulation with alisporivir
BR112017018861A2 (pt) 2015-03-04 2018-04-24 Board Of Regents, The Unibersity Of Texas System métodos para tratar câncer mantendo perda hemizigótica de tp53
MX2018010850A (es) 2016-03-10 2019-05-15 Univ Johns Hopkins Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2019004466A1 (ja) 2017-06-30 2019-01-03 興和株式会社 医薬
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐

Also Published As

Publication number Publication date
BR112021026876A2 (pt) 2022-02-22
AU2020300543A1 (en) 2022-02-24
CA3145824A1 (en) 2021-01-07
JP2022538898A (ja) 2022-09-06
EP3993809B1 (en) 2024-10-09
US20220304982A1 (en) 2022-09-29
EP3993809A1 (en) 2022-05-11
CN114599374A (zh) 2022-06-07
JP7704690B2 (ja) 2025-07-08
WO2021003279A1 (en) 2021-01-07
US12564600B2 (en) 2026-03-03
KR20220029717A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
JOP20220008A1 (ar) مثبطات parp1
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
AR109590A2 (es) Régimen posológico para inhibidores de comt
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
CO2019013020A2 (es) Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anticdh6
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
BR112022005657A2 (pt) Dispositivo de distribuição de fármaco
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
JOP20220020B1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
BR112018002342A2 (pt) polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
CR20190394A (es) Compuestos de inhibidores de autotaxina
CY1116579T1 (el) Φαρμακευτικες μορφες δοσολογιας ελεγχομενης απελευθερωσης
CO2024009571A2 (es) Inhibidores de parp1
BR112015018087A8 (pt) composto, composição farmacêutica e uso
EA200900912A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
MX2022003639A (es) Sistemas y métodos de suministro de fármacos.
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
EP4410373A3 (en) Nucleic acid simultaneously inhibiting expression of mtor gene and stat3 gene
MX390755B (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
BR112022023438A2 (pt) Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i
BR112021026876A2 (pt) Métodos para o tratamento do câncer